glp-1 incretin effect A pathophysiological update of the incretins A Tale of Two Incretins

A randomised controlled trial published in 2022 examined exenatide in individuals with AUD, finding no significant overall difference in alcohol consumption compared to placebo over a 26-week period, though a predefined subgroup analysis showed potential benefit specifically in participants with obesity

Wium-Andersen, I

This is the window where the medication begins to interact with the hunger centers in the hypothalamus

In that matched cohort, GLP-1 receptor agonist use was associated with a lower hazard of all-cause mortality, with a reported hazard ratio of 0.09, and a lower hazard of recurrence-free survival events, with a hazard ratio of 0.33 in unadjusted analyses

Keep reading to find out what you may experience when taking a GLP-1 to lose weight or manage your type 2 diabetes, how common the side effects are, and what steps you can take to help minimize them

The big takeaway